OverviewSuggest Edit

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
TypePublic
Founded2001
HQNeedham, MA, US
Websitechiasmapharma.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Mar 2020)48(+167%)
Revenue (FY, 2020)$1.1 M
Share Price (Aug 2021)$3.8
Cybersecurity ratingCMore

Key People/Management at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member
Show more

Chiasma Office Locations

Chiasma has offices in Needham, Waltham and Ness Ziona
Needham, MA, US (HQ)
140 Kendrick St Building C
Waltham, MA, US
460 Totten Pond Rd #530
Ness Ziona, IL
5 Golda Me'ir St
Show all (3)

Chiasma Financials and Metrics

Chiasma Revenue

Chiasma's revenue was reported to be $1.11 m in FY, 2020
USD

Revenue (Q1, 2021)

1.9m

Gross profit (Q1, 2021)

1.9m

Gross profit margin (Q1, 2021), %

96.5%

Net income (Q1, 2021)

(30.5m)

EBIT (Q1, 2021)

(18.0m)

Market capitalization (9-Aug-2021)

217.5m

Closing stock price (9-Aug-2021)

3.8

Cash (31-Mar-2021)

24.6m

EV

193.5m
Chiasma's current market capitalization is $217.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1m

Cost of goods sold

61.0k

Gross profit

1.0m

Gross profit Margin, %

94%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

142.0k1.9m

Cost of goods sold

3.0k67.0k

Gross profit

139.0k1.9m

Gross profit Margin, %

98%97%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

41.0m37.0m14.6m13.1m27.9m15.5m

Accounts Receivable

538.0k

Prepaid Expenses

1.8m2.2m3.9m6.4m

Inventories

2.3m2.1m11.0m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

63.3m140.9m39.1m30.5m28.5m19.0m18.4m12.1m15.2m13.8m11.2m10.1m20.6m19.7m42.6m52.2m72.8m24.6m

Accounts Receivable

179.0k1.0m

Prepaid Expenses

466.0k1.4m3.8m2.5m2.2m1.8m1.4m2.2m1.7m1.2m1.7m1.4m1.1m3.0m4.9m3.7m5.4m6.6m

Inventories

8.9m14.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(35.9m)(61.1m)(26.8m)(31.3m)(36.3m)(74.8m)

Depreciation and Amortization

201.0k433.0k152.0k88.0k55.0k172.0k

Inventories

(1.7m)674.0k(10.9m)

Accounts Payable

(161.0k)1.8m(1.6m)4.3m111.0k6.2m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(12.0m)(21.4m)(17.2m)(43.8m)(53.2m)(7.0m)(13.9m)(20.7m)(7.0m)(15.7m)(23.2m)(8.7m)(16.6m)(24.3m)(15.4m)(36.5m)(55.0m)(30.5m)

Depreciation and Amortization

98.6k146.2k59.0k153.0k373.0k40.0k79.0k119.0k23.0k46.0k69.0k16.0k29.0k42.0k26.0k73.0k122.0k51.0k

Inventories

(8.9m)(3.4m)

Accounts Payable

358.5k366.0k(457.0k)(670.0k)(613.0k)1.7m3.1m3.2m(751.0k)(1.2m)(1.9m)2.9m5.8m7.7m596.0k
USDQ2, 2015

Financial Leverage

-0.8 x
Show all financial metrics

Chiasma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Chiasma Online and Social Media Presence

Embed Graph

Chiasma News and Updates

Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency

Submission supported by previously announced data from Phase 3 MPOWERED™ study Submission supported by previously announced data from Phase 3 MPOWERED™ study

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences

-- New clinical data accepted for oral and e-Poster presentation at AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting --

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA

NEW YORK, May 7, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
Show more

Chiasma Blogs

Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral Octreotide Capsules for the Treatment of Acromegaly: Comparison of 2 Phase 3 Trial Results. Pituitary. 2021. https://doi.org/10.1007/s11102-021-01163-2

The post Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral Octreotide Capsules for the Treatment of Acromegaly: Comparison of 2 Phase 3 Trial Results. Pituitary. 2021. https://doi.org/10.1007/s11102-021-01163-2 appeared first on Chiasma.

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- NEEDHAM, Mass. , May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA),... The post Chiasma Presents Positive Patient-R…

Gordon MB, Fleseriu M, Dreval AV, et al. Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands In The MPOWERED Trail. Endocrine Abs. 2021; 73: PEP13.6. https://doi.org/10.1530/endoabs.73.PEP13.6

The post Gordon MB, Fleseriu M, Dreval AV, et al. Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands In The MPOWERED Trail. Endocrine Abs. 2021; 73: PEP13.6. https://doi.org/10.1530/endoabs.73.PEP13.6 appeared first on Chiasm…

Fleseriu M, Dreval AV, Pokramovich Y, et al. A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Endocrine Abs. 2021; 73: OC13.6. https://doi.org/10.1530/endoabs.73.OC13.6

The post Fleseriu M, Dreval AV, Pokramovich Y, et al. A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Endocrine Abs. 2021; 73: OC13.6. https://doi.org/10.1530/endoabs.73.OC13.6…

Biermasz N, Fleseriu M, Dreval AV, et al. Oral Octreotide Capsules Lowered Incidence And Improved Severity of Acromegaly Symptoms Compared To Injectable Somatostatin Receptor Ligands—Results From The MPOWERED Trial. Endocrine Abs. 2021; 73: PEP8.1. https://doi.org/10.1530/endoabs.73.PEP8.1

The post Biermasz N, Fleseriu M, Dreval AV, et al. Oral Octreotide Capsules Lowered Incidence And Improved Severity of Acromegaly Symptoms Compared To Injectable Somatostatin Receptor Ligands—Results From The MPOWERED Trial. Endocrine Abs. 2021; 73: PEP8.1. https://doi.org/10.1530/endoabs.73.PEP8.1 …

Freda P, Fleseriu M, Dreval AV, et al. Safety Results From MPOWERED, A Phase 3 Trial Of Oral Octreotide Capsules In Adults With Acromegaly. Endocrine Abs. 2021; 73: PEP3.2. https://doi.org/10.1530/endoabs.73.PEP3.2

The post Freda P, Fleseriu M, Dreval AV, et al. Safety Results From MPOWERED, A Phase 3 Trial Of Oral Octreotide Capsules In Adults With Acromegaly. Endocrine Abs. 2021; 73: PEP3.2. https://doi.org/10.1530/endoabs.73.PEP3.2 appeared first on Chiasma.
Show more

Chiasma Frequently Asked Questions

  • When was Chiasma founded?

    Chiasma was founded in 2001.

  • Who are Chiasma key executives?

    Chiasma's key executives are Roni Mamluk, Dana Gelbaum and Shoshie Katz.

  • How many employees does Chiasma have?

    Chiasma has 48 employees.

  • What is Chiasma revenue?

    Latest Chiasma annual revenue is $1.1 m.

  • What is Chiasma revenue per employee?

    Latest Chiasma revenue per employee is $23 k.

  • Who are Chiasma competitors?

    Competitors of Chiasma include Servier, Laboratorios Bago and USV.

  • Where is Chiasma headquarters?

    Chiasma headquarters is located at 140 Kendrick St Building C, Needham.

  • Where are Chiasma offices?

    Chiasma has offices in Needham, Waltham and Ness Ziona.

  • How many offices does Chiasma have?

    Chiasma has 3 offices.